• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Spartan Capital Securities, LLC Announces Key February Transactions

    3/7/25 4:56:47 PM ET
    $HCTI
    $LIPO
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HCTI alert in real time by email

    New York, NY, March 07, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a full-service investment banking firm, is pleased to announce a series of strategic transactions completed in February 2025, reinforcing its position as a trusted financial partner for companies across diverse industries.

    Spartan Capital successfully served as the sole placement agent for Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) in a $3.788 million private placement. This financing represents an important milestone in Lipella's efforts to advance its clinical pipeline and address significant unmet medical needs under the leadership of CEO Dr. Jonathan Kaufman.

    The firm also played a key role as Co-Placement Agent in Healthcare Triangle, Inc.'s (NASDAQ:HCTI) $15.2 million private placement, securing $14.2 million of the total offering. The proceeds will support Healthcare Triangle's strategic acquisitions, general corporate purposes, and working capital needs, enabling the company to further its mission of driving digital transformation in healthcare and life sciences through cloud enablement, cybersecurity, and data analytics.

    "These transactions highlight Spartan Capital's ability to deliver meaningful results for our clients," said John Lowry, CEO of Spartan Capital Securities, LLC. "We take pride in our role as a trusted partner, helping companies secure the capital they need to fuel innovation, execute strategic growth initiatives, and drive long-term success. Our investment banking team remains committed to delivering exceptional service and tailored financial solutions across diverse industries."

    Spartan Capital extends its gratitude to Sichenzia Ross Ference Carmel LLP for their expert legal representation of Spartan Capital in the Lipella Pharmaceuticals transaction and Sullivan & Worcester LLP for representing Lipella Pharmaceuticals. Additionally, we appreciate the contributions of RBW Capital Partners LLC (a division of Dawson James Securities, Inc.), Sichenzia Ross Ference Carmel LLP, and Manatt, Phelps & Phillips, LLP in the Healthcare Triangle placement.

    These February transactions exemplify Spartan Capital Securities' ongoing commitment to providing impactful investment banking solutions. With a deep understanding of market dynamics and a focus on delivering strategic financial solutions, Spartan Capital remains dedicated to supporting clients in achieving their long-term goals.

    As we continue into 2025, Spartan Capital is excited about the opportunities ahead and remains committed to delivering excellence in investment banking.

    About Spartan Capital Securities, LLC

    Spartan Capital Securities, LLC is a full-service, integrated financial services firm providing strategic investment banking solutions to high-net-worth individuals and institutions. With deep market expertise and a steadfast commitment to client success, Spartan Capital continues to set the standard for excellence in the financial industry.

    Contact:

    Spartan Capital Securities, LLC

    45 Broadway, 19th Floor

    New York, NY 10006

    [email protected]



    Primary Logo

    Get the next $HCTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HCTI
    $LIPO

    CompanyDatePrice TargetRatingAnalyst
    More analyst ratings

    $HCTI
    $LIPO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

      Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that topline data from the first two dose cohorts of its ongoing Phase 2a trial of LP-310 (liposomal tacrolimus oral rinse) for the treatment of Oral Lichen Planus (OLP) will be presented at the 2025 joint international meeting of the American Academy of Oral Me

      5/15/25 9:00:00 AM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on "Global Transformation in Oral Medicine"

      Joint meeting to be held in Las Vegas, May 14-17 Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute Topline study results demonstrate clinically meaningful improvements in OLP Visible lesion resolution during treatment; return toward baseline post-dosing supports localized activity PITTSBURGH, April 23, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that its abstract on LP-10 for the treatment of Oral Lichen Planus (OLP) has been accepted for podium presentation at

      4/23/25 8:30:00 AM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

      Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase 2b IND Submission and Broader Regulatory Engagement PITTSBURGH, April 22, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us," or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced positive topline results from the second cohort (0.50 mg) of its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal-tacrolimus oral rinse formulation of

      4/22/25 5:30:00 AM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCTI
    $LIPO
    Financials

    Live finance-specific insights

    See more

    $HCTI
    $LIPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $HCTI
    $LIPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $HCTI
    $LIPO
    Leadership Updates

    Live Leadership Updates

    See more
    • Healthcare Triangle, Inc. Releases Shareholder Update

      Highlights Market Opportunity and Recent Accretive Acquisition Awarded Top 100 Premier Partner Status at Amazon World Services & Premier Partner Status at Google Cloud PLEASANTON, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc., (NASDAQ:HCTI) ("HCTI" or the "Company") a leading provider of cloud and data transformation platform and solutions for healthcare and life sciences, today released a shareholder update: Dear Shareholders: Thank you for your continued commitment and investment in Healthcare Triangle, Inc . Our progress over the past year would not have been possible without your trust and belief in our mission. This is our first shareholder update since our

      1/20/22 8:30:00 AM ET
      $HCTI
      EDP Services
      Technology
    • Healthcare Triangle (HCTI) Acquires DevCool, an Electronic Health Record (EHR) Focused Healthcare IT and Managed Services Company

      PLEASANTON, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (HCTI), a leading provider of Healthcare and Life Sciences cloud transformation, managed services and data analytics platform company, announced today that it has acquired DevCool, Inc. ("DevCool"), ranked by Inc. 5000 as among the fastest growing private companies in USA in 2021. DevCool provides EHR Implementation and Managed Services to 6 of the top 10 hospitals in the USA and specializes in providing services to cancer research hospitals and university medical centres. The combined entity will focus on accelerating healthcare providers to adopt cloud technologies in improving clinical, operational, and fin

      12/13/21 8:00:00 AM ET
      $HCTI
      EDP Services
      Technology
    • Kaufman Jonathan H bought $7,590 worth of shares (10,000 units at $0.76), increasing direct ownership by 1% to 898,849 units (SEC Form 4)

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      5/15/24 4:39:19 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kaufman Jonathan H bought $45,452 worth of shares (55,000 units at $0.83), increasing direct ownership by 7% to 888,849 units (SEC Form 4)

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      3/19/24 6:21:08 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Kaufman Jonathan H

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      4/7/25 7:16:11 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Business Head Kannappan Lakshmanan acquired 304,180 shares, increasing direct ownership by 1,521% to 324,180 units (SEC Form 4)

      4 - Healthcare Triangle, Inc. (0001839285) (Issuer)

      4/2/25 5:13:23 PM ET
      $HCTI
      EDP Services
      Technology
    • Head of M&A Kizhakevilayil Shibu acquired 34,129 shares, increasing direct ownership by 171% to 54,129 units (SEC Form 4)

      4 - Healthcare Triangle, Inc. (0001839285) (Issuer)

      4/2/25 5:12:34 PM ET
      $HCTI
      EDP Services
      Technology
    • Healthcare Triangle, Inc. Appoints Anand Kumar as Interim CEO

      PLEASANTON, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc. (NASDAQ:HCTI) ("Healthcare Triangle," "HCTI" or the "Company"), a frontrunner in healthcare technology has announced the appointment of Anand Kumar as the interim Chief Executive Officer alongside his current role as the Chief Revenue Officer. Anand is committed to leading the Company's continued commitment to driving innovation in Health Care through the utilization of Digital transformation, Artificial Intelligence (AI) and Large Language Models (LLM). With a wealth of experience and a track record of successfully leading initiatives, Anand is strategically positioned to guide HCTI through its next phase of

      3/12/24 9:41:00 AM ET
      $HCTI
      EDP Services
      Technology

    $HCTI
    $LIPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

      SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      11/14/24 5:09:22 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

      SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      11/14/24 5:00:15 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc.

      SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      10/17/24 5:00:44 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCTI
    $LIPO
    SEC Filings

    See more
    • Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

      5/16/25 4:05:53 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B4 filed by Healthcare Triangle Inc.

      424B4 - Healthcare Triangle, Inc. (0001839285) (Filer)

      5/15/25 3:23:51 PM ET
      $HCTI
      EDP Services
      Technology
    • Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

      5/15/25 9:10:57 AM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care